Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Slightly Bullish +25

What Are Wall Street Analysts' Target Price for Amgen Stock? - Yahoo Finance

🧬 Amgen Inc. (AMGN) is a pharmaceutical company with an $182.4 billion market cap, focusing on discovering and delivering human therapeutics based on cellular and molecular biology.

📉 The stock has underperformed the broader S&P 500 Index over the past year, gaining only 17.1% compared to the index's 28.3% rally.

📊 On February 3, AMGN reported Q4 results with adjusted EPS of $5.29 and revenue of $9.9 billion, both exceeding Wall Street estimates.

🔮 Analysts expect full-year adjusted EPS between $21.60 and $23, with a fiscal 2026 diluted EPS growth expectation of 1.5% to $22.16.

🏆 The company has beaten the consensus estimate in earnings for each of the last four quarters, highlighting an impressive earnings surprise history.

🗳️ Among 36 analysts covering AMGN, the consensus rating is a "Moderate Buy," with ratings including 13 "Strong Buys," 18 "Holds," and two "Strong Sells."

📉 The bullish sentiment among analysts has decreased compared to three months ago, when 14 analysts suggested a "Strong Buy" rating.

🔍 Canaccord Genuity initiated coverage on April 21 with a "Hold" rating and a price target of $366, implying an 8.3% upside from current levels.

💰 The mean analyst price target is set at $357.84, representing a 5.9% premium to AMGN's current stock price.

🚀 The street-high price target stands at $432, which suggests a significant upside potential of 27.8% for shareholders.

Bullish Signals
  • AMGN reported Q4 results on Feb. 3, with its shares closing up more than 8% in the subsequent trading session.
  • The company's adjusted EPS of $5.29 exceeded Wall Street expectations of $4.76, demonstrating strong earnings performance.
  • Revenue reached $9.9 billion, beating Wall Street forecasts of $9.5 billion, highlighting robust demand for its therapeutics.
  • AMGN expects full-year adjusted EPS in the range of $21.60 to $23, and revenue in the range of $37 billion to $38.4 billion, indicating solid growth guidance.
  • The stock has beaten the consensus estimate in each of the last four quarters, showcasing a consistent earnings surprise history.
  • With a market cap of $182.4 billion, AMGN focuses on innovating novel medicines based on cellular and molecular biology within human therapeutics.
  • Among 36 analysts covering AMGN stock, 13 have provided 'Strong Buy' ratings, reflecting significant analyst confidence in the company's prospects.
  • The mean price target of $357.84 represents a 5.9% premium to current price levels, offering upside potential for investors.
  • The Street-high price target of $432 suggests an upside potential of 27.8%, indicating bullish sentiment from Wall Street analysts.
Risk Factors
  • Shares of Amgen (AMGN) have underperformed the broader market over the past year, gaining only 17.1% compared to the S&P 500 Index's rally of nearly 28.3%.
  • Despite beating Wall Street expectations recently, the consensus analyst rating is "Moderate Buy" which includes six bearish ratings (one Moderate Sell and two Strong Sells) among 36 analysts.
  • The number of "Strong Buy" ratings decreased from 14 to 13 over the last three months, indicating a softening in bullish sentiment among Wall Street analysts.
  • Analyst Canaccord Genuity initiated coverage with a "Hold" rating and a price target of $366, suggesting limited upside potential compared to peers.
  • Amgen's stock is currently trading below its analyst consensus mean price target of $357.84, implying the stock may still be undervalued despite recent gains.
Full Analysis
Amgen Inc. (AMGN), a drug manufacturing giant headquartered in Thousand Oaks, California with a market capitalization of $182.4 billion, has underperformed the broader market over the past year. While the company's shares gained 17.1%, the S&P 500 Index rallied nearly 28.3%. On a year-to-date basis, AMGN stock is up 3.3% compared to the SPX's 4.2% rise, and it also trails the Invesco Pharmaceuticals ETF (PJP), which gained about 26.9% over the past year though the stock has outperformed the ETF's 1.3% YTD losses. This underperformance persists despite positive recent performance relative to broader sector peers. On Feb. 3, Amgen reported its Q4 results, with shares closing up more than 8% in the subsequent trading session. The company delivered an adjusted EPS of $5.29, exceeding Wall Street expectations of $4.76, and generated revenue of $9.9 billion against forecasts of $9.5 billion. Amgen expects full-year adjusted EPS between $21.60 and $23 with revenue ranging from $37 billion to $38.4 billion. For fiscal 2026, analysts expect AMGN's diluted EPS to grow 1.5% to $22.16 on a year-to-date basis, and the company has a track record of beating consensus estimates in each of its last four quarters. Wall Street analysts maintain a consensus rating of "Moderate Buy" for AMGN among the 36 firms covering the stock, based on 13 "Strong Buy" ratings, two "Moderate Buys," 18 "Holds," one "Moderate Sell," and two "Strong Sells." This configuration is less bullish than three months ago, when 14 analysts suggested a "Strong Buy." On Apr. 21, Canaccord Genuity initiated coverage with a "Hold" rating and set a price target of $366, implying an 8.3% upside from current levels. The mean price target stands at $357.84, representing a 5.9% premium to current prices, while the Street-high price target is $432, suggesting a potential upside of 27.8%.